Encapsulation of SAAP-148 in Octenyl Succinic Anhydride-Modified Hyaluronic Acid Nanogels for Treatment of Skin Wound Infections
Chronic wound infections colonized by bacteria are becoming more difficult to treat with current antibiotics due to the development of antimicrobial resistance (AMR) as well as biofilm and persister cell formation. Synthetic antibacterial and antibiofilm peptide (SAAP)-148 is an excellent alternative for treatment of such infections but suffers from limitations related to its cationic peptidic nature and thus instability and possible cytotoxicity, resulting in a narrow therapeutic window. Here, we evaluated SAAP-148 encapsulation in nanogels composed of octenyl succinic anhydride (OSA)-modified hyaluronic acid (HA) to circumvent these limitations. SAAP-148 was efficiently (>98%) encapsulated with high drug loading (23%), resulting in monodispersed anionic OSA-HA nanogels with sizes ranging 204-253 nm. Nanogel lyophilization in presence of polyvinyl alcohol maintained their sizes and morphology. SAAP-148 was sustainedly released from lyophilized nanogels (37-41% in 72 h) upon reconstitution. Lyophilized SAAP-148-loaded nanogels showed similar antimicrobial activity as SAAP-148 against planktonic and biofilm-residing AMR Staphylococcus aureus and Acinetobacter baumannii. Importantly, formulated SAAP-148 showed reduced cytotoxicity against human erythrocytes, primary human skin fibroblasts and human keratinocytes. Additionally, lyophilized SAAP-148-loaded nanogels eradicated AMR S. aureus and A. baumannii colonizing a 3D human epidermal model, without inducing any cytotoxicity in contrast to SAAP-148. These findings indicate that OSA-HA nanogels increase SAAP-148's therapeutic potential for treatment of skin wound infections.
Media Type: |
Electronic Article |
---|
Year of Publication: |
2023 |
---|---|
Publication: |
2023 |
Contained In: |
To Main Record - volume:15 |
---|---|
Contained In: |
Pharmaceutics - 15(2023), 2 vom: 28. Jan. |
Language: |
English |
---|
Contributors: |
van Gent, Miriam E [Author] |
---|
Links: |
---|
Keywords: |
AMP formulation |
---|
Notes: |
Date Revised 01.03.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3390/pharmaceutics15020429 |
---|---|
Clinical Trials/ Publications: |
|
funding: |
|
---|---|
Supporting institution / Project title: |
|
PPN (Catalogue-ID): |
NLM353458783 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM353458783 | ||
003 | DE-627 | ||
005 | 20231226060037.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/pharmaceutics15020429 |2 doi | |
028 | 5 | 2 | |a pubmed24n1178.xml |
035 | |a (DE-627)NLM353458783 | ||
035 | |a (NLM)36839751 | ||
035 | |a (PII)429 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a van Gent, Miriam E |e verfasserin |4 aut | |
245 | 1 | 0 | |a Encapsulation of SAAP-148 in Octenyl Succinic Anhydride-Modified Hyaluronic Acid Nanogels for Treatment of Skin Wound Infections |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 01.03.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Chronic wound infections colonized by bacteria are becoming more difficult to treat with current antibiotics due to the development of antimicrobial resistance (AMR) as well as biofilm and persister cell formation. Synthetic antibacterial and antibiofilm peptide (SAAP)-148 is an excellent alternative for treatment of such infections but suffers from limitations related to its cationic peptidic nature and thus instability and possible cytotoxicity, resulting in a narrow therapeutic window. Here, we evaluated SAAP-148 encapsulation in nanogels composed of octenyl succinic anhydride (OSA)-modified hyaluronic acid (HA) to circumvent these limitations. SAAP-148 was efficiently (>98%) encapsulated with high drug loading (23%), resulting in monodispersed anionic OSA-HA nanogels with sizes ranging 204-253 nm. Nanogel lyophilization in presence of polyvinyl alcohol maintained their sizes and morphology. SAAP-148 was sustainedly released from lyophilized nanogels (37-41% in 72 h) upon reconstitution. Lyophilized SAAP-148-loaded nanogels showed similar antimicrobial activity as SAAP-148 against planktonic and biofilm-residing AMR Staphylococcus aureus and Acinetobacter baumannii. Importantly, formulated SAAP-148 showed reduced cytotoxicity against human erythrocytes, primary human skin fibroblasts and human keratinocytes. Additionally, lyophilized SAAP-148-loaded nanogels eradicated AMR S. aureus and A. baumannii colonizing a 3D human epidermal model, without inducing any cytotoxicity in contrast to SAAP-148. These findings indicate that OSA-HA nanogels increase SAAP-148's therapeutic potential for treatment of skin wound infections | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a AMP formulation | |
650 | 4 | |a SAAP-148 | |
650 | 4 | |a antimicrobial peptide | |
650 | 4 | |a cutaneous application | |
650 | 4 | |a hyaluronic acid-based nanogels | |
650 | 4 | |a skin wound infections | |
700 | 1 | |a van Baaren, Tom |e verfasserin |4 aut | |
700 | 1 | |a Kłodzińska, Sylvia N |e verfasserin |4 aut | |
700 | 1 | |a Ali, Muhanad |e verfasserin |4 aut | |
700 | 1 | |a Dolezal, Natasja |e verfasserin |4 aut | |
700 | 1 | |a van Doodewaerd, Bjorn R |e verfasserin |4 aut | |
700 | 1 | |a Bos, Erik |e verfasserin |4 aut | |
700 | 1 | |a de Waal, Amy M |e verfasserin |4 aut | |
700 | 1 | |a Koning, Roman I |e verfasserin |4 aut | |
700 | 1 | |a Drijfhout, Jan Wouter |e verfasserin |4 aut | |
700 | 1 | |a Nielsen, Hanne Mørck |e verfasserin |4 aut | |
700 | 1 | |a Nibbering, Peter H |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pharmaceutics |d 2010 |g 15(2023), 2 vom: 28. Jan. |w (DE-627)NLM204303303 |x 1999-4923 |7 nnns |
773 | 1 | 8 | |g volume:15 |g year:2023 |g number:2 |g day:28 |g month:01 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/pharmaceutics15020429 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 15 |j 2023 |e 2 |b 28 |c 01 |